Innovation1 Biotech Inc.
IVBT · OTC
8/31/2023 | 8/31/2022 | 8/31/2021 | 8/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.00 | -0.00 | -0.00 |
| FCF Yield | -3.61% | -133.53% | -5.39% | -19,934.31% |
| EV / EBITDA | -3.05 | -0.07 | 0.47 | -0.64 |
| Quality | ||||
| ROIC | 42.71% | -36.56% | 398.59% | 11.81% |
| Gross Margin | 0.00% | 0.00% | 53.86% | -150.97% |
| Cash Conversion Ratio | 0.10 | 0.08 | -0.03 | 0.16 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -66.13% | -58.71% |
| Free Cash Flow Growth | 80.19% | -10,197.62% | 92.59% | 47.57% |
| Safety | ||||
| Net Debt / EBITDA | -0.03 | -0.01 | 0.02 | -0.64 |
| Interest Coverage | -5.43 | -952.12 | -1.17 | -0.17 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -45.13 | 0.08 | 0.08 |
| Cash Conversion Cycle | -2,419.35 | -23.69 | -6,389.17 | -8,943.04 |